Towards a Life
Free from Cancer
This is CuraCell
CuraCell develops cell-based immunotherapies for cancer treatment focusing on TILs (Tumor Infiltrating Lymphocytes), an investigational therapy aimed at a durable cure for solid tumor cancers.
The company is initiating its first clinical program targeting indications with high prevalence and the potential to make a significant impact for cancer patients worldwide.
Learn moreCuraCell's
CuraCell advanced activation and expansion platform, CytoPLYTM amplifies cytotoxicity of T-cell therapies such as TILs and TCR-Ts. CytoPLYTM enables T-cell therapies to advance into cold solid tumor cancers with large unmet medical needs. Applicable to a broad range of solid tumors, CuraCell’s first TIL product generation aims at late-stage prostate cancer and colorectal cancer.
Promising results from patient-named treatments lay a strong foundation for CuraCell’s next clinical step.
Learn moreOur Resources
CuraCell is committed to advancing cancer therapy through innovative research, strong partnerships, and global collaborations.
By utilizing our advanced facilities, we strive to develop impactful solutions that bring better treatments to patients with solid cancer.
Market Opportunity
CuraCell is tackling the urgent need for effective treatments for solid tumor cancer, which impact millions of patients worldwide.
Discover how we can collaborate to advance cell therapy and make a meaningful difference for cancer patients.
Careers
Do you want to make an impact for cancer patients? Are you ready for a new challenge? Please don't hesitate to reach out to us, we are always looking for new talent.
Learn more